CVRx (NASDAQ:CVRX – Get Rating) is one of 213 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare CVRx to similar companies based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, profitability and earnings.
Institutional and Insider Ownership
65.9% of CVRx shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 14.3% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current recommendations and price targets for CVRx and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CVRx presently has a consensus price target of $20.84, suggesting a potential upside of 297.03%. As a group, “Surgical & medical instruments” companies have a potential upside of 57.00%. Given CVRx’s stronger consensus rating and higher probable upside, analysts clearly believe CVRx is more favorable than its peers.
Earnings & Valuation
This table compares CVRx and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|CVRx||$13.04 million||-$43.08 million||-0.11|
|CVRx Competitors||$1.15 billion||$84.54 million||-503.18|
CVRx’s peers have higher revenue and earnings than CVRx. CVRx is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares CVRx and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About CVRx (Get Rating)
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.